Camblong Jurgi sold $93K of SOPH
Camblong Jurgi (Executive Chairman) sold 17,685 shares of SOPHiA GENETICS SA (SOPH) at $5.28 on 2026-07-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and post-transaction holdings, executed under a pre-arranged 10b5-1 plan.
Market read
This disclosure may slightly influence sentiment, but it does not introduce new operational or financial guidance for SOPH.
What to watch
Traders may over-weight insider sales; without accompanying buys, guidance changes, or operational news, the incremental information is small.
Background
The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS, reported by Executive Chairman Camblong Jurgi.
Ticker impact
Executive Chairman Camblong Jurgi sold 17,685 shares of SOPHiA GENETICS at $5.2772 on 2026-07-07 under a 10b5-1 plan.
Limited near-term impact; any effect is likely sentiment-driven and short-lived.
The filing is a Form 4 insider transaction with an explicitly stated Rule 10b5-1 pre-arranged plan, which typically reduces the likelihood of immediate information content.
Market effects
No clear sector read-through; this is company-specific insider trading disclosure.
None indicated.
None indicated.
Counterpoint
The sale could be purely liquidity-driven under the 10b5-1 plan, implying no bearish signal about SOPH fundamentals.
Key entities
- issuerSOPHiA GENETICS SA
Subject of the Form 4 insider sale by its Executive Chairman.
- insiderCamblong Jurgi
Executive Chairman and reporting person who sold shares under a 10b5-1 plan.
